The price of Cybin Inc (AMEX:CYBN) shares last traded on Wall Street rose 14.62% to $0.63.
Based on available information, 6 analysts follow Cybin Inc (AMEX:CYBN). The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $10.00 and a low of $0.74, we find $3.50. Given the previous closing price of $0.55, this indicates a potential upside of 536.36 percent. CYBN stock price is now 76.12% away from the 50-day moving average and 72.09% away from the 200-day moving average. The market capitalization of the company currently stands at $151.29M.
Among analysts, 0 rate the stock a hold while 6 rate it a buy. Brokers who have rated the stock have averaged $4.17 as their price target over the next twelve months.
A total of 15.71% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in CYBN stock. A new stake in Cybin Inc shares was purchased by FNY INVESTMENT ADVISERS, LLC during the first quarter worth $88,000. INTEROCEAN CAPITAL GROUP, LLC invested $63,000 in shares of CYBN during the first quarter. In the first quarter, LPL FINANCIAL LLC acquired a new stake in Cybin Inc valued at approximately $18,000. MARIETTA WEALTH MANAGEMENT, LLC acquired a new stake in CYBN for approximately $13,000. HRT FINANCIAL LP purchased a new stake in CYBN valued at around $9,000 in the second quarter. In total, there are 72 active investors with 10.75% ownership of the company’s stock.
A candlestick chart of Cybin Inc (AMEX: CYBN) showed a price of $0.5600 on Monday morning. During the past 12 months, Cybin Inc has had a low of $0.21 and a high of $0.65. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 2.61, and a quick ratio of 2.61. The fifty day moving average price for CYBN is $0.3620 and a two-hundred day moving average price translates $0.3678 for the stock.
The latest earnings results from Cybin Inc (AMEX: CYBN) was released for Jun, 2023.
Cybin Inc(CYBN) Company Profile
Cybin Inc., a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company’s development pipeline includes CYB003, a deuterated psilocybin analog, which is in Phase 1/2a clinical trial to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine, which is in Phase 1 clinical trial for treating generalized anxiety disorders; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation. It has also developed EMBARK, a psychological support model that integrates clinical approaches to promote supportive healing with psychedelic medicine. The company is headquartered in Toronto, Canada.
